Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 399,570,400
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 9,034 M
  • EBITDA $ 17,420 M
  • 60-Month Beta 0.36
  • Price/Sales 7.18
  • Price/Cash Flow 15.32
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 22.96% (+0.45%)
  • Historical Volatility 27.72%
  • IV Percentile 34%
  • IV Rank 15.71%
  • IV High 51.27% on 04/08/25
  • IV Low 17.68% on 02/19/25
  • Expected Move (DTE 6) 5.25 (2.32%)
  • Put/Call Vol Ratio 0.49
  • Today's Volume 10,902
  • Volume Avg (30-Day) 14,773
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 305,295
  • Open Int (30-Day) 326,865
  • Expected Range 220.83 to 231.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 3.37
  • Number of Estimates 8
  • High Estimate 3.54
  • Low Estimate 3.30
  • Prior Year 2.16
  • Growth Rate Est. (year over year) +56.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
215.65 +4.84%
on 11/06/25
239.29 -5.52%
on 11/13/25
+9.31 (+4.29%)
since 11/05/25
3-Month
207.61 +8.90%
on 09/08/25
244.81 -7.65%
on 10/01/25
+13.52 (+6.36%)
since 09/05/25
52-Week
164.39 +37.53%
on 04/09/25
244.81 -7.65%
on 10/01/25
+49.91 (+28.33%)
since 12/05/24

Most Recent Stories

More News
3 Dividend Aristocrats on the Edge of a Big Move

Discover three high-yield Dividend Aristocrats showing strong fundamentals and analyst support as they set up for a potential breakout.

SYY : 73.10 (-0.46%)
PG : 143.45 (-1.31%)
ABBV : 226.08 (-1.15%)
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers

NORTH CHICAGO, Ill. , Dec. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances...

ABBV : 226.08 (-1.15%)
3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

KO : 70.00 (-0.64%)
JNJ : 201.93 (-0.27%)
ABBV : 226.08 (-1.15%)
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI ® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s...

ABBV : 226.08 (-1.15%)
These Are The Best Dividend Picks for Over 20% Gains

In 2025, markets rewarded investors with dividend income-paying stocks that returned 20% or more. Nexstar ...

IBM : 307.94 (-0.02%)
ABBV : 226.08 (-1.15%)
PM : 147.81 (-0.52%)
NXST : 189.01 (-0.44%)
Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

$NASX : 23,578.13 (+0.31%)
LLY : 1,010.31 (-0.41%)
ABBV : 226.08 (-1.15%)
3 Highest-Yielding Dividend Aristocrats to Buy Today

These three dividend aristocrats offer a trifecta: Low volatility, analyst ratings, and the highest yields among the group.

CVX : 150.00 (-1.48%)
XOM : 116.54 (-0.51%)
ABBV : 226.08 (-1.15%)
1 Surging Stock with Exciting Potential and 2 Facing Challenges

1 Surging Stock with Exciting Potential and 2 Facing Challenges

BHF : 65.35 (-0.26%)
ESE : 195.59 (-3.31%)
ABBV : 226.08 (-1.15%)
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec  One biotech will receive a year of laboratory and office...

ABBV : 226.08 (-1.15%)
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

NORTH CHICAGO, Ill. , Nov. 24, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025. Management will participate...

ABBV : 226.08 (-1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 232.74
2nd Resistance Point 230.99
1st Resistance Point 228.54
Last Price 226.08
1st Support Level 224.34
2nd Support Level 222.59
3rd Support Level 220.14

See More

52-Week High 244.81
Last Price 226.08
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar